Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects

Keverprazan, a novel potassium‐competitive acid blocker, was approved for treating acid‐related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and pharmacodynamics (PDs) of multiple doses of keverprazan. This was a randomized, positive‐/placebo‐controlled, phase Ic trial. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Sufeng, Xie, Lijun, Zhou, Chen, Wang, Lu, Chen, Juan, Ding, Sijia, Zhu, Bei, Su, Mei, Shao, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582672/
https://www.ncbi.nlm.nih.gov/pubmed/37533172
http://dx.doi.org/10.1111/cts.13598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582672/
https://www.ncbi.nlm.nih.gov/pubmed/37533172
http://dx.doi.org/10.1111/cts.13598

Ejemplares similares